1 4349 137 MIR-155 AND MIR-122 EXPRESSION OF SPERMATOZOA IN OBESE SUBJECTS. OBESITY IS CHARACTERIZED BY MILD CHRONIC INFLAMMATION THAT IS LINKED WITH IMPAIRED IRON HOMEOSTASIS. STUDIES IN HUMAN AND MURINE SHOW THAT THERE IS A TRANSGENERATIONAL EPIGENETIC INHERITANCE VIA THE GAMETES IN OBESITY; HOWEVER, THERE IS LITTLE INFORMATION ON CHANGES IN THE EXPRESSION OF MICRORNAS RELATED TO INFLAMMATION AND IRON HOMEOSTASIS IN SPERMATOZOA FROM OBESE SUBJECTS. THE PRESENT STUDY INVESTIGATED THE EXPRESSION OF MICRORNAS RELATED TO INFLAMMATION (MIR-21 Y MIR-155) AND IRON NUTRITION (MIR-122 AND MIR-200B) IN PLASMA, PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) AND SPERMATOZOA FROM NORMOZOOSPERMIC CONTROLS (CN; N = 17; BMI: 24.6 +/- 2.0) AND OBESE (OB; N = 17; BMI: 32.6 +/- 4.4) MEN. TO DETERMINE THE INFLAMMATION LEVELS, WE MEASURED IL-6, TNF-ALPHA, AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP1) BY MAGNETIC LUMINEX((R)) ASSAY. MRNA EXPRESSION OF IL6, TNF-ALPHA, AND HEPCIDIN (HAMP) IN PBMC WERE EVALUATED BY RT-QPCR. THE ANALYSIS OF MICRORNAS WAS PERFORMED USING THE TAQMAN((R)) ASSAYS. THE IRON CONTENT IN PBMC, SEMINAL PLASMA, AND SPERMATOZOA WAS DETERMINED BY INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS). HIGH SERUM IL6, TNF-ALPHA, AND MCP1 LEVELS WERE OBSERVED IN OB GROUP (P < 0.05). GENE EXPRESSION ANALYSIS SHOWED AN INCREASED ABUNDANCE RELATIVE OF TNF-ALPHA (P = 0.018), HAMP (P = 0.03), AND IL6 (P = 0.02) IN PBMC FROM OBESE SUBJECTS. ALSO, WE OBSERVED HIGH LEVELS OF SERUM FERRITIN (P = 0.03), IRON CONTENT IN SEMINAL PLASMA (P = 0.04), AND SPERMATOZOA (P = 0.002), BUT LOWER SERUM FE (P = 0.007) IN OBESE SUBJECTS. IN THE OB GROUP, A HIGH EXPRESSION OF MIR-155 (P = 0.02) AND MIR-21 (P = 0.03) WAS OBSERVED IN PBMC AND MIR-122 (P = 0.03) IN PLASMA. IN SPERM, BOTH MIR-155 (P = 0.004) AND MIR-122 (P = 0.028) WERE HIGH IN THE OB GROUP. OUR RESULTS SHOWED THAT OBESE SUBJECTS HAVE INCREASED EXPRESSIONS OF MIR-155 AND MIR-122, TWO MICRORNAS THAT WERE PREVIOUSLY RELATED WITH INFLAMMATION AND IRON METABOLISM, RESPECTIVELY, AT BOTH THE SYSTEMIC AND SPERM LEVELS. 2018 2 6830 23 [HOW HISTONE DEACETYLASE 3 CONTROLS HEPCIDIN EXPRESSION AND HEPATITIS C VIRUS REPLICATION]. THE KEY ROLE OF HISTONE DEACETYLASES (HDAC) IN THE REGULATION OF THE CELLULAR RESPONSE TO INFECTION WITH THE HEPATITIS C VIRUS (HCV) WAS FIRST DEMONSTRATED IN 2008. WHEN STUDYING THE METABOLISM OF IRON IN THE LIVER TISSUES OF PATIENTS WITH CHRONIC HEPATITIS C, THE AUTHORS FOUND THAT THE EXPRESSION OF THE HEPCIDIN GENE (HAMP), A HORMONE REGULATOR OF IRON EXPORT, IS MARKEDLY REDUCED IN HEPATOCYTES UNDER CONDITIONS OF OXIDATIVE STRESS CAUSED BY VIRAL INFECTION. HDAC WERE INVOLVED IN THE REGULATION OF HEPCIDIN EXPRESSION THROUGH THE CONTROL OF ACETYLATION LEVEL OF HISTONES AND TRANSCRIPTION FACTORS, PRIMARILY STAT3, ASSOCIATED WITH THE HAMP PROMOTER. THE PURPOSE OF THIS REVIEW WAS TO SUMMARIZE CURRENT DATA ON THE FUNCTIONING OF THE HCV-HDAC3-STAT3-HAMP REGULATORY CIRCUIT AS AN EXAMPLE OF A WELL-CHARACTERIZED INTERACTION BETWEEN THE VIRUS AND THE EPIGENETIC APPARATUS OF THE HOST CELL. 2023 3 6832 33 [HYPOMETHYLATION OF TNF-ALPHA GENE PROMOTER IN THE PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B LIVER FAILURE]. OBJECTIVE: THE PRESENT STUDY WAS DESIGNED TO INVESTIGATE THE POSSIBLE EPIGENETIC ALTERATION IN THE PROMOTER OF TNF-ALPHA IN THE PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B LIVER FAILURE (ACHBLF). METHODS: THE METHYLATION OF TNF-ALPHA PROMOTER IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) WAS MEASURED BY METHYLATION SPECIFIC PCR (MSP). THE LEVEL OF SERUM TNF-ALPHA WAS DETERMINED BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA). MODEL FOR END-STAGE LIVER DISEASE (MELD) WAS PERFORMED FOR THE EVALUATION OF LIVER FAILURE. RESULTS: THE SERUM LEVEL OF TNF-ALPHA IN PATIENTS WITH ACHBLF(44.9260 +/- 26.48523) WAS HIGHER THAN THAT IN CHB (18.92505 +/- 9.04461) AND HEALTHY CONTROLS (11.9172 +/- 5.04612) (P < 0.05). MOREOVER, THE SERUM TNF-ALPHA LEVEL WAS SIGNIFICANTLY DECREASED IN METHYLATION GROUP AS COMPARED TO UNMETHYLAITON GROUP IN PATIENTS WITH ACHBLF (P < 0.05). MELD WAS NOT SIGNIFICANTLY DIFFERENT BETWEEN METHYLATED AND UNMETHYLATED GROUP OF ACHBLF PATIENTS (P > 0.05). IN ADDITION, THE SERUM LEVEL OF TNF-ALPHA WAS FOUND TO BE POSITIVELY CORRELATED WITH SERUM TOTAL BILIRUBIN (R = 0.891, P < 0.01) AND MELD SCORE (R = 0.792, P < 0.01), BUT TO BE NEGATIVELY CORRELATED WITH PROTHROMBIN ACTIVITY (R = - 0.511, P < 0.05) IN PATIENTS WITH ACHBLF. CONCLUSION: THE TNF-ALPHA METHYLATION PATTEN IS STABLE FOR THE LIVER FAILURE, SUGGESTING THE EFFECT OF ENVIRONMENT ON METHYLATION. 2011 4 6243 33 THE MECHANISM OF APOLIPROTEIN A1 DOWN-REGULATED BY HEPATITIS B VIRUS. BACKGROUND: HEPATITIS B VIRUS (HBV) INFECTION CORRELATED WITH THE DEVELOPMENT OF CIRRHOSIS, LIVER FAILURE AND HEPATOCELLULAR CARCINOMA (HCC), POSES A HUGE HEALTH BURDEN ON THE GLOBAL COMMUNITY. HOWEVER, THE PATHOGENESIS OF CHRONIC HEPATITIS B (CHB) REMAINS UNCLEAR. APOLIPOPROTEIN A1 (APOA1) MAINLY SECRETED BY HEPATOCYTES, REPRESENTS THE MAJOR PROTEIN COMPONENT OF HIGH-DENSITY LIPOPROTEIN. APOA1 SECRETION MAY BE DISRUPTED BY HBV INFECTION. IN THIS STUDY, WE MAINLY INVESTIGATED THE MOLECULAR MECHANISM OF APOA1 DOWN REGULATED BY HBV FOR REVEALING THE PATHOGENESIS OF CHB. METHODS: APOA1 EXPRESSION IN LIVERS OF CHB PATIENTS AS WELL AS HEALTHY CONTROLS WERE PERFORMED BY REAL-TIME PCR (RT-PCR) AND WESTERN BLOT. THE SERUM APOA1 LEVELS WERE MEASURED BY ENZYMED-LINKED IMMUNOSORBENT ASSAY (ELISA). EXPRESSION OF APOA1 MRNA AND PROTEIN LEVELS WERE PERFORMED BY RT-PCR AND WESTERN BLOT IN HUMAN HEPATOMA HEPG2 CELLS AND SUBLINE HEPG2.2.15 CELLS. HBV EXPRESSION CONSTRUCT, PHBV1.3 WERE TRANSFECTED INTO HEPG2, THE CHANGES OF APOA1 MRNA AND PROTEIN EXPRESSION WERE DETECTED BY RT-PCR AND WESTERN BLOT. TO FURTHER STUDY THE MECHANISM OF APOA1 DOWN REGULATION BY HBV, 11 CPG ISLANDS IN APOA1 PROMOTOR WERE TESTED FOR DNA METHYLATION STATUS BY MSP. HEPG2.2.15 CELL LINES WERE TREATED WITH DNA METHYLTRANSFERASE INHIBITOR 5-AZA-DEOXYCYTIDINE (5-AZA-DC), THEN, EXPRESSION OF APOA1 MRNA AND HBV PARTICLES IN THE SUPERNATANT, AS WELL AS APOA1 PROTEIN LEVELS WERE DETECTED BY RT-PCR AND WESTERN BLOT. SECRETION OF HBSAG AND HBEAG IN HEPG2 CELLS COTRANSFECTED WITH PAPOA1 AND PHBV1.3 CONSTRUCTS WAS TESTED BY ELISA. MEANWHILE, SECRETION OF HBSAG AND HBEAG IN THE SUPERNATANT WERE QUANTIFIED BY ELISA IN THE HEPG2.2.15 CELLS TREATED WITH 5-AZA-DC PLUS APOA1 SIRNA. RESULTS: EXPRESSION OF APOA1 MRNA AND PROTEIN LEVELS, AS WELL AS SERUM APOA1 LEVELS IN CHB PATIENTS WERE DECREASED CORRESPONDING HEALTHY CONTROLS IN VIVO. IN ADDITION, THE EXPRESSION OF APOA1 MRNA AND PROTEIN LEVELS WERE DOWN REGULATED IN HEPG2.2.15 CELLS CORREPONDING HEPG2 CELLS, 11 CPG ISLANDS IN APOA1 PROMOTER WERE TESTED FOR METHYLATION STATUS BY MSP IN HEPG2.2.15 CELLS COMPARED TO HEPG2 CELLS, WHILE TWO CPG ISLANDS WERE FOUND HYPERMETHYLATED. EXPRESSION OF APOA1 MRNA AND PROTEIN LEVELS WERE INCREASED IN HEPG2.2.15 CELLS TREATED WITH DNA METHYLTRANSFERASE INHIBITOR 5-AZA-DC. FURTHERMORE, OVEREXPRESSION OF APOA1 CAN ENHANCE HBV EXPRESSION IN HEPG2 CELLS WHILE THE INHIBITORY EFFECT OF 5-AZA-DC ON HBV EXPRESSION WAS COMPLETELY ABOLISHED BY BLOCKING 5-AZA-DC-INDUCED UP-REGULATION OF APOA1 USING RNAI. CONCLUSIONS: EPIGENETIC SILENCING OF APOA1 GENE EXPRESSION BY CPG ISLAND DNA HYPERMETHYLATION INDUCED BY HBV MAY CONTRIBUTE TO THE PATHOGENESIS OF CHB. 2016 5 2893 27 GAS5 RS2067079 AND MIR-137 RS1625579 FUNCTIONAL SNPS AND RISK OF CHRONIC HEPATITIS B VIRUS INFECTION AMONG EGYPTIAN PATIENTS. HEPATITIS B VIRUS (HBV) INFECTION IS A SIGNIFICANT HEALTH ISSUE WORLDWIDE.. WE ATTEMPTED TO FULFILL THE MOLECULAR MECHANISMS OF EPIGENETIC AND GENETIC FACTORS ASSOCIATED WITH CHRONIC HBV (CHBV). EXPRESSION LEVELS OF THE LNCRNA GROWTH ARREST-SPECIFIC 5 (GAS5) AND MIR-137 AND THEIR CORRESPONDING SNPS, RS2067079 (C/T) AND RS1625579 (G/T) WERE ANALYZED IN 117 CHBV PATIENTS AND 120 CONTROLS TO INVESTIGATE THE PROBABLE ASSOCIATION BETWEEN THESE BIOMARKERS AND CHBV PATHOGENESIS IN THE EGYPTIAN POPULATION. SERUM EXPRESSION LEVELS OF GAS5 AND MIR-137 WERE SIGNIFICANTLY DOWN-REGULATED IN CASES VS CONTROLS. REGARDING GAS5 (RS2067079), THE MUTANT TT GENOTYPE SHOWED AN INCREASED RISK OF CHBV (P < 0.001), WHILE THE DOMINANT CC WAS A PROTECTIVE FACTOR (P = 0.004). REGARDING MIR-137 RS1625579, THE MUTANT GENOTYPE TT WAS REPORTED AS A RISK FACTOR FOR CHBV (P < 0.001) AND THE NORMAL GG GENOTYPE WAS A PROTECTIVE FACTOR, P < 0.001. THE SERUM GAS5 WAS SIGNIFICANTLY HIGHER IN THE MUTANT TT GENOTYPE OF GAS5 SNP AS COMPARED TO THE OTHER GENOTYPES (P = 0.007). CONCERNING MIR-137 RS1625579, THE MUTANT TT GENOTYPE WAS SIGNIFICANTLY ASSOCIATED WITH A LOWER SERUM EXPRESSION LEVEL OF MIR-137 (P = 0.018). WE REVEALED THE DYSREGULATED EXPRESSION LEVELS OF GAS5 AND MIR-137 LINKED TO THEIR FUNCTIONING SNPS WERE ASSOCIATED WITH CHBV RISK AND MIGHT ACT AS POTENTIAL THERAPEUTIC TARGETS. 2021 6 4246 37 METHYLATION STATUS OF THE T-CADHERIN GENE PROMOTOR IN PERIPHERAL BLOOD MONONUCLEAR CELLS IS ASSOCIATED WITH HBV-RELATED HEPATOCELLULAR CARCINOMA PROGRESSION. DNA METHYLATION IS ONE OF THE EPIGENETIC MECHANISMS TO REGULATE GENE EXPRESSION AND FREQUENTLY OCCURS IN HUMAN CANCER CELLS. T-CADHERIN (CDH13) IS A NEW MEMBER OF THE CADHERIN SUPERFAMILY AND POSSESSES MULTIPLE FUNCTIONS. OUR STUDY INCLUDED 26 NORMAL CONTROLS (NCS), 65 CHRONIC HEPATITIS B PATIENTS (CHB), 14 LIVER CIRRHOSIS PATIENTS (LC) AND 157 HEPATOCELLULAR CARCINOMA PATIENTS (HCC). WE MAINLY FOCUSED ON THE MRNA EXPRESSION AND METHYLATION STATUS OF CDH13 IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS), WHICH WERE DETECTED BY SEMI-QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (RT-QPCR) AND METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP) RESPECTIVELY. THE CDH13 MRNA LEVEL WAS LOWER IN HCC, ESPECIALLY IN EARLY-STAGE OF HCC THAN IN NCS AND CHB GROUPS (P < 0.05). METHYLATION FREQUENCY OF THE CDH13 PROMOTER WAS SIGNIFICANTLY HIGHER IN HCC PATIENTS THAN IN THE NCS AND CHB GROUPS (67.52 % VS 0.00 %, P < 0.001, 67.52 % VS 52.31 %, P < 0.05, RESPECTIVELY). CDH13 MRNA LEVEL WAS SIGNIFICANTLY AND RELATIVELY LOWER IN METHYLATED GROUPS THAN IN UNMETHYLATED GROUPS AMONG THE WHOLE PARTICIPANTS. THE METHYLATION LEVEL OF CDH13 PROMOTER IN HCC MIGHT BE INFLUENCED OR PARTLY INFLUENCED BY SOME CRITICAL FACTORS SUCH AS TBIL, ALB AND AFP (P < 0.05). AS AN IMPORTANT FACTOR IN SIGNALING PATHWAY REGULATING BY CDH13 TO PROMOTE CARCINOGENESIS, JNK LEVEL WAS SIGNIFICANTLY HIGHER IN HCC WHICH HAD A HIGHER METHYLATION FREQUENCY THAN IN NCS, CHB AND LC (P < 0.05). FURTHERMORE, THE COMBINATION OF THE METHYLATED CDH13 LEVEL AND AFP LEVEL SHOWED A BETTER SCORE: AUC = 0.796 (SE = 0.031, 95 %CI 0.735-0.857; P < 0.001) IN MALE AND AUC = 0.832 (SE = 0.057, 95 %CI 0.721-0.944; P < 0.001) IN FEMALE COMPARED TO AFP ALONE FOR DIAGNOSING HCC FROM NCS, CHB AND LC. THE METHYLATION OF CDH13 PROMOTER WAS AN INDEPENDENT PREDICTOR FOR ASSESSING THE PROGNOSIS OF HCC PATIENTS (R=-1.378 P < 0.05). IN CONCLUSION, HYPERMETHYLATION OF CDH13 IN PBMCS WAS ASSOCIATED WITH THE UNDEREXPRESSION OF MRNA AND THE HIGH RISK OF HCC. THE METHYLATION STATUS OF THE CDH13 PROMOTER IN PBMCS WAS A POTENTIAL NONINVASIVE BIOMARKER TO PREDICT THE PROGNOSIS OF HCC PATIENTS. 2020 7 388 34 AN INTEGRATED ANALYSIS OF SOCS1 DOWN-REGULATION IN HBV INFECTION-RELATED HEPATOCELLULAR CARCINOMA. PERSISTENT INFLAMMATION TOGETHER WITH GENETIC/EPIGENETIC ABERRATIONS IS STRONGLY ASSOCIATED WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION-RELATED HEPATOCARCINOGENESIS. HERE, WE INVESTIGATED THE ALTERATIONS OF THE SUPPRESSOR OF CYTOKINE SIGNALLING (SOCS) FAMILY GENES IN HBV-RELATED HEPATOCELLULAR CARCINOMA (HCC). A TOTAL OF 116 PATIENTS WITH HCC WERE ENROLLED IN THIS STUDY. THE METHYLATION STATUSES OF SOCS1-7 AND CISH GENES WERE QUANTITATIVELY MEASURED AND CLINICOPATHOLOGICAL SIGNIFICANCE OF SOCS1 METHYLATION WAS STATISTICALLY ANALYSED. THE GENE COPY NUMBER VARIATION WAS ASSAYED BY ACGH. LUCIFERASE REPORTER ASSAY AND WESTERN BLOT WERE USED TO DETECT THE INVOLVEMENT OF SOCS1 IN P53 SIGNALLING. WE FOUND HIGH FREQUENCIES OF SOCS1 GENE HYPERMETHYLATION IN BOTH TUMOUR (56.03%) AND ADJACENT NONTUMOUR TISSUES (54.31%), BUT TUMOUR TISSUES EXHIBITED INCREASED METHYLATION INTENSITY (24.01% VS 13.11%, P < 0.0001), PARTICULARLY IN PATIENTS WITH LARGER TUMOUR SIZE OR CIRRHOSIS BACKGROUND (P < 0.0001). IN ADDITION, THE FREQUENCY AND INTENSITY OF SOCS1 HYPERMETHYLATION IN TUMOUR TISSUES WERE BOTH SIGNIFICANTLY HIGHER THAN THOSE IN NONTUMOUR TISSUES IN MALE GENDER PATIENTS AND IN PATIENTS >/=45 YEARS OLD (P = 0.0214 AND P < 0.0001, P = 0.0232 AND P < 0.0001, RESPECTIVELY). SOCS1 GENE DELETION WAS FOUND IN 8 OF 25 ACGH ASSAYED TUMOUR SPECIMENS, WHICH WAS ASSOCIATED WITH LOWER SOCS1 MRNA EXPRESSION (P = 0.0448). FURTHERMORE, ECTOPIC SOCS1 OVEREXPRESSION COULD ACTIVATE THE P53 SIGNALLING PATHWAY IN HCC CELL LINES. HYPERMETHYLATION OF SOCS2-7 AND CISH GENES WAS SELDOM FOUND IN HCC. OUR RESULTS SUGGESTED THAT THE GENE LOSS AND EPIGENETIC SILENCING OF SOCS1 WERE STRONGLY ASSOCIATED WITH HBV-RELATED HCC. 2014 8 3303 27 HIGH-FREQUENCY P16(INK) (4A) PROMOTER METHYLATION IS ASSOCIATED WITH HISTONE METHYLTRANSFERASE SETDB1 EXPRESSION IN SPORADIC CUTANEOUS MELANOMA. EPIGENETIC MECHANISMS PARTICIPATE IN MELANOMA DEVELOPMENT AND PROGRESSION. THE EFFECT OF HISTONE MODIFICATIONS AND THEIR CATALYSING ENZYMES OVER EUCHROMATIC PROMOTER DNA METHYLATION IN MELANOMA REMAINS UNCLEAR. THIS STUDY INVESTIGATED THE POTENTIAL ASSOCIATION OF P16(INK) (4A) PROMOTER METHYLATION WITH HISTONE METHYLTRANSFERASE SETDB1 EXPRESSION IN GREEK PATIENTS WITH SPORADIC MELANOMA AND THEIR CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS. PROMOTER METHYLATION WAS DETECTED BY METHYLATION-SPECIFIC PCR IN 100 PERIPHERAL BLOOD SAMPLES AND 58 MELANOMA TISSUES FROM THE SAME PATIENTS. CELL PROLIFERATION (KI-67 INDEX), P16(INK) (4A) AND SETDB1 EXPRESSION WERE EVALUATED BY IMMUNOHISTOCHEMISTRY. HIGH-FREQUENCY PROMOTER METHYLATION (25.86%) WAS OBSERVED IN TISSUE SAMPLES AND CORRELATED WITH INCREASED CELL PROLIFERATION (P = 0.0514). P16(INK) (4A) PROMOTER METHYLATION WAS HIGHER IN VERTICAL GROWTH-PHASE (60%) MELANOMAS THAN IN RADIAL (40%, P = 0.063) AND THOSE DISPLAYING EPIDERMAL INVOLVEMENT (P = 0.046). IMPORTANTLY, P16(INK) (4A) METHYLATION CORRELATED WITH INCREASED MELANOMA THICKNESS ACCORDING TO BRESLOW INDEX (P = 0.0495) AND MARGINALLY WITH INCREASED CLARK LEVEL (I/II VS III/IV/V, P = 0.070). LOW (1-30%) P16(INK) (4A) EXPRESSION WAS DETECTED AT THE MAJORITY (19 OF 54) OF MELANOMA CASES (35.19%), BEING MARGINALLY CORRELATED WITH TUMOR LYMPHOCYTIC INFILTRATION (P = 0.078). SETDB1 NUCLEAR IMMUNOREACTIVITY WAS OBSERVED IN 47 OF 57 (82.46%) CASES, WHEREAS 27 OF 57 (47.37%) SHOWED CYTOPLASMIC IMMUNOEXPRESSION. CYTOPLASMIC SETDB1 EXPRESSION CORRELATED WITH HIGHER FREQUENCY OF P16(INK) (4A) METHYLATION AND P16(INK) (4A) EXPRESSION (P = 0.033, P = 0.011, RESPECTIVELY). INCREASED NUCLEAR SETDB1 LEVELS WERE ASSOCIATED WITH HIGHER MITOTIC COUNT (0-5/MM(2) VS >5/MM(2) , P = 0.0869), ADVANCED CLARK LEVEL (III-V, P = 0.0380), EPIDERMAL INVOLVEMENT (P = 0.0331) AND THE NON-CHRONIC SUN EXPOSURE-ASSOCIATED MELANOMA TYPE (P = 0.0664). OUR DATA DEMONSTRATE FOR THE FIRST TIME THE ASSOCIATION OF HISTONE METHYLTRANSFERASE SETDB1 WITH FREQUENT METHYLATION OF THE EUCHROMATIC P16(INK) (4A) PROMOTER AND SEVERAL PROGNOSTIC PARAMETERS IN MELANOMAS. 2014 9 2746 36 EXPRESSION ANALYSIS OF LONG NON-CODING RNAS AND THEIR TARGET GENES IN MULTIPLE SCLEROSIS PATIENTS. MULTIPLE SCLEROSIS (MS) IS A PROGRESSIVE CHRONIC AUTOIMMUNE-MEDIATED DISEASE. RECENTLY, LONG NON-CODING RNAS (LNCRNAS) ARE CHARACTERIZED TO PARTICIPATE IN THE ADJUSTMENT OF IMMUNE RESPONSES. HERE, WE EVALUATED THE EXPRESSION LEVELS OF GSTT1-AS1 AND IFNG-AS1 LNCRNAS AND THEIR TARGETS (TNF AND IFNG, RESPECTIVELY) IN IRANIAN MS PATIENTS.IN THIS CASE-CONTROL STUDY, 50 RELAPSING-REMITTING MS PATIENTS AND 50 HEALTHY SUBJECTS WERE RECRUITED. EXPRESSIONS OF GSTT1-AS1 AND IFNG-AS1 LNCRNAS, AS WELL AS TNF AND IFNG GENES, WERE ASSESSED IN THEIR PERIPHERAL BLOOD SAMPLES BY SYBR GREEN-BASED REAL-TIME QUANTITATIVE PCR.EXPRESSION LEVELS OF GSTT1-AS1 AND IFNG-AS1 LNCRNAS WERE BOTH SIGNIFICANTLY DOWNREGULATED (P VALUES 0.032 AND 0.013, RESPECTIVELY). ON THE OTHER HAND, THE EXPRESSION OF TNF AND IFNG SHOWED INCREASED LEVELS, HOWEVER, DID NOT REACH STATISTICAL SIGNIFICANCE AFTER OUR ANALYSIS (P > 0.05). SPEARMAN CORRELATION ANALYSIS SHOWED THAT GSTT1-AS1 HAD A SIGNIFICANT POSITIVE MODERATE CORRELATION WITH IFNG-AS1 (R = 0.541, P < 0.0001), IFNG (R = 0.329, P = 0.001), AND TNF (R = 0.204, P = 0.041). ALSO, IFNG-AS1 REVEALED THE SAME CORRELATION WITH IFNG (R = 0.475, P < 0.0001) AS WELL AS TNF (R = 0.399, P < 0.0001). FURTHERMORE, GSTT1-AS1 (R = 0.313, P = 0.027) AND (IFNG R = 0.478, P < 0.0001) DEMONSTRATED A SIGNIFICANT POSITIVE CORRELATION WITH AGE AT ONSET.BRIEFLY, THE CURRENT STUDY PROVIDED FOR THE FIRST TIME DYSREGULATION OF GSTT1-AS1 AND IFNG-AS LNCRNAS NETWORK IN MS, WHICH HIGHLIGHTS THE SIGNIFICANT ROLE OF EPIGENETIC PATHWAYS IN THIS AUTOIMMUNE DISORDER. LARGER SAMPLE SIZE AND FURTHER INVESTIGATION ASSAYS COULD SHED LIGHT ON THE UNDERLYING MECHANISMS IN THIS AREA OF SCIENCE. 2019 10 3453 30 HYPOMETHYLATED UBIQUITIN-CONJUGATING ENZYME2 Q1 (UBE2Q1) GENE PROMOTER IN THE SERUM IS A PROMISING BIOMARKER FOR HEPATITIS B VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA. ABERRANT DNA METHYLATION, WHICH CAN BE DETECTED IN CIRCULATING CELL-FREE DNA (CFDNA), IS ONE OF THE MAJOR EPIGENETIC ALTERATIONS IN HEPATOCELLULAR CARCINOMA (HCC). UBE2Q1, A PUTATIVE MEMBER OF THE UBIQUITIN-CONJUGATING ENZYME FAMILY, MIGHT PLAY SUBSTANTIAL ROLES IN TUMORIGENESIS. HOWEVER, THE METHYLATION STATUS OF THE UBE2Q1 GENE IN HCC REMAINS UNKNOWN. WE AIMED TO DETERMINE THE METHYLATION STATUS OF THE UBE2Q1 GENE PROMOTER AND TO EVALUATE ITS POTENTIAL CLINICAL SIGNIFICANCE FOR HCC DETECTION. THE METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP) ASSAY WAS USED TO DETECT THE UBE2Q1 GENE METHYLATION STATUS IN SERUM SAMPLES FROM 80 PATIENTS WITH HEPATITIS B VIRUS (HBV)-RELATED HCC, 40 PATIENTS WITH LIVER CIRRHOSIS (LC), 40 PATIENTS WITH CHRONIC HEPATITIS B (CHB), AND 20 HEALTHY CONTROLS (HCS). SIGNIFICANTLY LOWER METHYLATION FREQUENCIES WERE DETECTED IN HCC PATIENTS (33.75%) COMPARED WITH LC PATIENTS (55.00%, P = 0.026) AND CHB PATIENTS (60.00%, P = 0.006) AND HCS (65.00%, P = 0.011). HYPOMETHYLATION OF THE UBE2Q1 GENE WAS NEGATIVELY ASSOCIATED WITH THE TUMOR NODE METASTASIS STAGE (R(S) = -0.30, P = 0.008). THE UBE2Q1 GENE METHYLATION STATUS COMBINED WITH ALPHA FETOPROTEIN USING CUT-OFF POINTS OF 20, 200 AND 400 NG/ML SHOWED SENSITIVITY AND SPECIFICITY VALUES OF 58.8% AND 75.0%, 53.8% AND 87.5%, AND 37.5% AND 88.7%, RESPECTIVELY, AND YIELDED A SIGNIFICANTLY INCREASED AREA UNDER THE ROC CURVE (0.720, 0.760 AND 0.694, RESPECTIVELY) FOR DISCRIMINATING HCC FROM LC AND CHB. OUR STUDY RESULTS SUGGEST THAT HYPOMETHYLATION OF THE UBE2Q1 GENE PROMOTER IS A POTENTIAL BIOMARKER FOR DETECTING HBV-ASSOCIATED HCC. 2017 11 2125 30 EPIGENETIC INACTIVATION OF DLX4 IS ASSOCIATED WITH DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA. ABERRANT DNA METHYLATION OF VARIOUS GENES HAS BEEN IDENTIFIED TO BE ASSOCIATED WITH DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA (CML). OUR STUDY WAS INTENDED TO INVESTIGATE DLX4 METHYLATION PATTERN IN DIFFERENT CLINICAL STAGES OF CML AND FURTHER DETERMINE ITS ROLE IN REGULATING DLX4 EXPRESSION. REAL-TIME QUANTITATIVE METHYLATION-SPECIFIC PCR AND BISULFITE SEQUENCING PCR WERE APPLIED TO DETECT DLX4 METHYLATION. 5-AZA-2'-DEOXYCYTIDINE (5-AZA-DC) WAS USED FOR DEMETHYLATION STUDIES. DLX4 WAS SIGNIFICANTLY HYPERMETHYLATED IN CML PATIENTS (P = 0.002) ESPECIALLY IN BLASTIC PHASE (BC) STAGE (P < 0.001) AS COMPARED WITH CONTROLS. MOREOVER, DLX4 METHYLATION LEVEL IN BC STAGE WAS SIGNIFICANTLY HIGHER THAN IN CHRONIC PHASE (CP) STAGE (P < 0.001). DLX4 METHYLATION DENSITY WAS SIGNIFICANTLY INCREASED DURING THE PROGRESSION OF CML AMONG THE TESTED TWO PATIENTS (P < 0.001). DLX4 HYPERMETHYLATION OCCURRED WITH THE HIGHEST INCIDENCE IN BC STAGE (83%), LOWER INCIDENCE IN ACUTE PHASE (AP) STAGE (43%), AND THE LOWEST INCIDENCE IN CP STAGE (26%) (P = 0.001). MOREOVER, T(9; 22) WITH ADDITIONAL ALTERATION CASES HAD SIGNIFICANTLY HIGHER FREQUENCY OF DLX4 HYPERMETHYLATION COMPARED WITH THE OTHER CYTOGENETICS (P = 0.010). SIGNIFICANTLY NEGATIVE CORRELATION WAS OBSERVED BETWEEN DLX4 METHYLATION AND DLX4-TV2 (THE SHORTER DLX4 ISOFORM) EXPRESSION (R = -0.382, P = 0.001, N = 78) BUT NOT BETWEEN DLX4 METHYLATION AND BP1 (THE LONGER DLX4 ISOFORM) EXPRESSION (R = 0.134, P = 0.244, N = 78) IN CML PATIENTS. BOTH DLX4-TV2 AND BP1 MRNA WERE SIGNIFICANTLY INCREASED AFTER 5-AZA-DC TREATMENT IN K562 CELL LINE (P < 0.001). OUR STUDY INDICATED THAT HYPERMETHYLATION OF DLX4 CORRELATED WITH DISEASE PROGRESSION OF CML. MOREOVER, DLX4 EXPRESSION WAS REGULATED BY ITS METHYLATION IN CML. 2015 12 2311 29 EPIGENETIC REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2 IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS. GROUP IVA CYTOSOLIC PHOSPHOLIPASE A2 (CPLA2 OR PLA2G4A) IS A KEY ENZYME THAT CONTRIBUTES TO INFLAMMATION VIA THE GENERATION OF ARACHIDONIC ACID AND EICOSANOIDS. WHILE MUCH IS KNOWN ABOUT REGULATION OF CPLA2 BY POSTTRANSLATIONAL MODIFICATION SUCH AS PHOSPHORYLATION, LITTLE IS KNOWN ABOUT ITS EPIGENETIC REGULATION. IN THIS STUDY, TREATMENT WITH HISTONE DEACETYLASE (HDAC) INHIBITORS, TRICHOSTATIN A (TSA), VALPROIC ACID, TUBACIN AND THE CLASS I HDAC INHIBITOR, MS-275, WERE FOUND TO INCREASE CPLA2ALPHA MESSENGER RNA (MRNA) EXPRESSION IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS. CO-TREATMENT OF THE HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR, ANACARDIC ACID, MODULATED UPREGULATION OF CPLA2ALPHA INDUCED BY TSA. SPECIFIC INVOLVEMENT OF CLASS I HDACS AND HAT IN CPLA2ALPHA REGULATION WAS FURTHER SHOWN, AND A TIP60-SPECIFIC HAT INHIBITOR, NU9056, MODULATED THE UPREGULATION OF CPLA2ALPHA INDUCED BY MS-275. IN ADDITION, CO-TREATMENT OF WITH HISTONE METHYLTRANSFERASE (HMT) INHIBITOR, 5'-DEOXY-5'-METHYLTHIOADENOSINE (MTA) SUPPRESSED TSA-INDUCED CPLA2ALPHA UPREGULATION. THE ABOVE CHANGES IN CPLA2 MRNA EXPRESSION WERE REFLECTED AT THE PROTEIN LEVEL BY WESTERN BLOTS AND IMMUNOCYTOCHEMISTRY. CHROMATIN IMMUNOPRECIPITATION (CHIP) SHOWED TSA INCREASED BINDING OF TRIMETHYLATED H3K4 TO THE PROXIMAL PROMOTER REGION OF THE CPLA2ALPHA GENE. CELL INJURY AFTER TSA TREATMENT AS INDICATED BY LACTATE DEHYDROGENASE (LDH) RELEASE WAS MODULATED BY ANACARDIC ACID, AND A ROLE OF CPLA2 IN MEDIATING TSA-INDUCED INJURY SHOWN, AFTER CO-INCUBATION WITH THE CPLA2 SELECTIVE INHIBITOR, ARACHIDONOYL TRIFLUOROMETHYL KETONE (AACOCF3). TOGETHER, RESULTS INDICATE EPIGENETIC REGULATION OF CPLA2 AND THE POTENTIAL OF SUCH REGULATION FOR TREATMENT OF CHRONIC INFLAMMATION. 2016 13 2863 27 FUNCTION OF DNA METHYLTRANSFERASE 3A IN LEAD (PB(2+) )-INDUCED CYCLOOXYGENASE-2 GENE. LEAD IONS (PB(2+) ) ARE TOXIC INDUSTRIAL POLLUTANTS ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES IN HUMANS AND ANIMALS. PREVIOUSLY, WE FOUND THAT PB(2+) IONS INDUCE COX-2 GENE EXPRESSION VIA THE EGF RECEPTOR/NUCLEAR FACTOR-KAPPAB SIGNAL TRANSDUCTION PATHWAY IN EPIDERMOID CARCINOMA CELL LINE A431. IN THIS STUDY, TO SEE WHETHER PB(2+) IONS AFFECT COX-2 EXPRESSION BY EPIGENETIC MECHANISMS, WE LOOKED AT THE MRNAS OF DNA METHYLTRANSFERASES (DNMTS) USING REAL-TIME PCR OF TOTAL RNA FROM THESE CELLS. CELLS EXPOSED TO PB(2+) HAD LOW LEVELS OF DNMT3A MRNA, WHEREAS THE LEVELS OF DNMT1 AND DNMT3B MRNAS REMAINED UNCHANGED. PRETREATMENT OF CELLS WITH DNMT INHIBITOR 5-AZA-2'-DEOXYCYTIDINE (5 MUM) FOLLOWED BY PB(2+) (1 MUM) SIGNIFICANTLY INCREASED LEVELS OF COX-2 MRNA COMPARED WITH CELLS TREATED WITH PB(2+) ALONE. OVEREXPRESSION OF TUMOR SUPPRESSOR GENE RB CORRELATED WITH AN INCREASE IN COX-2 MRNA AND A DECREASE IN DNMT3A MRNA. CONVERSELY, OVEREXPRESSION OF TRANSCRIPTION FACTOR E2F1 CORRELATED WITH A DECREASE IN COX-2 MRNA AND AN INCREASE IN DMNT3A MRNA. PRETREATMENT WITH EGFR INHIBITORS AG1478 AND PD153035 SIGNIFICANTLY LIMITED PB(2+) -INDUCED REDUCTION IN DNMT3A MRNA. IN ADDITION, GENE KNOCKDOWN OF DNMT3A WITH SHORT HAIRPIN RNA CORRELATED WITH INCREASED COX-2 MRNA INDUCED BY PB(2+) . OUR FINDINGS SUGGEST PB(2+) IONS INDUCE COX-2 EXPRESSION INDIRECTLY BY REDUCING DNMT3A METHYLATION OF THE COX-2 PROMOTER VIA TRANSCRIPTION FACTORS RB AND E2F1. 2015 14 2688 21 EVIDENCE THAT METHYLATION OF HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA IN LIVER TISSUES OF PATIENTS WITH CHRONIC HEPATITIS B MODULATES HBV REPLICATION. EPIGENETIC FACTORS MAY MODULATE CHRONIC HEPATITIS B VIRAL INFECTION BY AFFECTING VIRION GENE TRANSCRIPTION. THE AIM OF THIS STUDY WAS TO COMPARE THE METHYLATION STATUS OF THE INTRAHEPATIC COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) CPG ISLAND 2 AND HBV REPLICATION CAPABILITY. HBV CCCDNA WAS EXTRACTED FROM LIVER BIOPSIES OF 55 HBSAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (32 HBEAG-POSITIVE AND 23 HBEAG-NEGATIVE), AND WAS ANALYZED FOR METHYLATION STATUS AND QUANTITY. THE TWO HPA II RECOGNITION SEQUENCES CCPGG IN THE CPG ISLAND 2 WERE METHYLATED IN INFECTED LIVER TISSUES FROM 24 (43.6%) OF 55 PATIENTS. POSITIVE RATIOS OF CCCDNA METHYLATION WERE SIGNIFICANTLY HIGHER IN HBEAG-NEGATIVE PATIENTS (15/23, 65.2%) THAN HBEAG-POSITIVE PATIENTS (9/32, 28.1%) (P < 0.05). THE PERCENTAGE OF METHYLATED-CCCDNA/TOTAL-CCCDNA OF HBEAG-NEGATIVE SAMPLES (A MEDIAN OF 48%, RANGING FROM 5% TO 83%) WAS SIGNIFICANTLY HIGHER (P < 0.001) THAN HBEAG-POSITIVE SAMPLES (A MEDIAN OF 14%, RANGING FROM 0.26% TO 35%). RATIOS OF RELAXED CIRCULAR DNA (RCDNA) TO CCCDNA MOLECULES REVEALED THAT CCCDNA METHYLATION CORRELATED WITH IMPAIRED VIRION PRODUCTIVITY IN HBEAG-POSITIVE INDIVIDUALS (P < 0.05). THE BISULFITE DNA SEQUENCING SHOWED THAT METHYLATION DENSITY WAS SIGNIFICANTLY HIGHER IN HBEAG-NEGATIVE THAN IN HBEAG-POSITIVE PATIENTS (P < 0.05). THE METHYLATION LEVEL OF THE CPG ISLAND 2 OF THE CCCDNA IN HBEAG-NEGATIVE PATIENTS WAS HIGHER THAN THAT IN HBEAG-POSITIVE PATIENTS, SUGGESTING THAT HBV CCCDNA METHYLATION MAY BE RELEVANT TO REPLICATION CAPABILITY OF HBV. 2009 15 428 25 ANTI-INFLAMMATORY ACTIVITY OF MIODESIN: MODULATION OF INFLAMMATORY MARKERS AND EPIGENETIC EVIDENCE. PURPOSE: TO INVESTIGATE THE EFFECTS OF A COMBINED HERBAL MEDICINE MIODESIN ON THE INFLAMMATORY RESPONSE OF KEY CELLS INVOLVED IN THE ACUTE AND CHRONIC INFLAMMATORY PROCESSES AS WELL AS THE POSSIBLE EPIGENETIC INVOLVEMENT. METHODS: AFTER THE ESTABLISHMENT OF THE IC(50) DOSE, THE CHONDROCYTE, KERATINOCYTE, AND MACROPHAGE CELL LINES WERE PRETREATED FOR 2 HOURS WITH MIODESIN (200 MUG/ML) AND STIMULATED WITH LPS (1 MUG/ML) FOR 24 HOURS. THE SUPERNATANT WAS USED TO MEASURE THE LEVELS OF CYTOKINES (IL-1BETA, IL-6, IL-8, AND TNF-ALPHA) AND CHEMOKINES (CCL2, CCL3, AND CCL5), AND THE CELLS WERE USED TO EXTRACT THE MRNA FOR THE TRANSCRIPTION FACTOR (NF-KAPPABETA), INFLAMMATORY ENZYMES (COX-1, COX-2, PLA2, AND INOS), AND CHEMOKINES (CCL2, CCL3, AND CCL5). RESULTS: MIODESIN INHIBITED THE RELEASE OF LPS-INDUCED CYTOKINES (IL-1BETA, IL-6, IL-8, AND TNF-ALPHA; P < 0.01) AND CHEMOKINES (CCL2, CCL3, AND CCL5; P < 0.01) AND THE EXPRESSION OF THE TRANSCRIPTION FACTOR (NF-KAPPABETA; P < 0.01), INFLAMMATORY ENZYMES (COX-1, COX-2, PLA2, INOS; P < 0.01), AND CHEMOKINES (CCL2, CCL3, AND CCL5; P < 0.01). IN ADDITION, THE EVALUATION OF EPIGENETIC MECHANISM REVEALED THAT MIODESIN DID NOT INDUCE CHANGES IN DNA METHYLATION, ASSURING THE GENETIC SAFENESS OF THE COMPOUND IN TERMS OF THE INFLAMMATORY RESPONSE. CONCLUSIONS: MIODESIN PRESENTS ANTI-INFLAMMATORY PROPERTIES, INHIBITING HYPERACTIVATION OF CHONDROCYTES, KERATINOCYTES, AND MACROPHAGES, INVOLVING EPIGENETICS IN SUCH EFFECTS. 2020 16 3448 31 HYPERMETHYLATION OF THE N-MYC DOWNSTREAM-REGULATED GENE 2 PROMOTER IN PERIPHERAL BLOOD MONONUCLEAR CELLS IS ASSOCIATED WITH LIVER FIBROSIS IN CHRONIC HEPATITIS B. DNA METHYLATION IS A FUNDAMENTAL EPIGENETIC MODIFICATION TO REGULATE GENE EXPRESSION. N-MYC DOWNSTREAM-REGULATED GENE (NDRG) 2 IS A CYTOPLASMIC PROTEIN AND PARTICIPATES IN THE PATHOGENESIS OF LIVER FIBROSIS. IN THIS STUDY, THE MRNA EXPRESSION AND METHYLATION STATUS OF NDRG2 WAS EVALUATED IN PATIENTS WITH CHRONIC HEPATITIS B (CHB). THE STUDY INCLUDED 143 CHB PATIENTS AND 65 NORMAL CONTROLS (NC). THE MRNA EXPRESSION OF NDRG2 IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) WAS DETECTED BY QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION. THE METHYLATION STATUS OF THE NDRG2 PROMOTER IN PBMCS WAS DETECTED BY METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION. THE NDRG2 MRNA LEVEL WAS LOWER IN THE CHB GROUP THAN IN THE NC GROUP (P < 0.001). METHYLATION FREQUENCY OF THE NDRG2 PROMOTER WAS SIGNIFICANTLY HIGHER IN CHB PATIENTS THAN IN THE NC GROUP (52.44% VS. 26.15%, P < 0.001). IMPORTANTLY, THE RELATIVE EXPRESSION LEVELS OF NDRG2 MRNA WERE SIGNIFICANTLY LOWER IN THE METHYLATED GROUP THAN IN THE UNMETHYLATED GROUP IN BOTH CHB PATIENTS AND NC (P < 0.001). FURTHERMORE, A LOWER MRNA LEVEL AND HYPERMETHYLATION OF NDRG2 WERE ASSOCIATED WITH LIVER FIBROSIS AND INFLAMMATION GRADE IN CHB. THE ASPARTATE AMINOTRANSFERASE-TO-PLATELET RATIO INDEX (APRI) SCORE IS WIDELY USED TO PREDICT LIVER FIBROSIS. THE MRNA EXPRESSION LEVELS AND METHYLATION STATUS OF NDRG2 SHOWED A BETTER SCORE COMPARED TO APRI FOR DISCRIMINATING THE SEVERITY OF LIVER FIBROSIS. IN CONCLUSION, HYPERMETHYLATION OF NDRG2 IN PBMCS WAS CORRELATED WITH DECREASED MRNA EXPRESSION AND WITH LIVER FIBROSIS. THE METHYLATION STATUS OF THE NDRG2 PROMOTER IN PBMCS IS A POTENTIAL NONINVASIVE BIOMARKER TO PREDICT THE SEVERITY OF LIVER FIBROSIS. 2017 17 3866 35 JHDM1D AND HDAC1-3 MRNA EXPRESSION LEVELS IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. BACKGROUND: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS A CHRONIC RELAPSING AUTOIMMUNE DISEASE CHARACTERIZED BY PRODUCTION OF AUTOANTIBODIES AGAINST A SERIES OF NUCLEAR ANTIGENS AND BY CHRONIC INFLAMMATION. THE ETIOLOGY OF SLE IS THE RESULT OF INTERACTIONS BETWEEN GENETIC, EPIGENETIC, HORMONAL, AND ENVIRONMENTAL FACTORS. CHANGES IN HISTONE ACETYLATION AND METHYLATION CONTRIBUTE TO STRUCTURAL CHROMATIN MODIFICATIONS. OBJECTIVE: WE STUDIED THE HISTONE DEMETHYLASE JHDM1D AND HISTONE DEACETYLASES HDAC1, HDAC2, AND HDAC3 TRANSCRIPT LEVELS IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) FROM PATIENTS DIAGNOSED WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). FURTHERMORE, THE ASSOCIATION OF JHDM1D, HDAC1, HDAC2, AND HDAC3 TRANSCRIPT LEVELS WITH GENDER, AGE, AND MAJOR CLINICAL MANIFESTATIONS WERE ANALYZED. MATERIALS AND METHODS: REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION (RQ-PCR) ANALYSIS WAS USED TO DETERMINE JHDM1D, HDAC1, HDAC2, AND HDAC3 MRNA EXPRESSION LEVELS IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) FROM 30 PATIENTS WITH SLE AND 36 HEALTHY CONTROLS. RESULTS: SIGNIFICANTLY LOWER HDAC2 TRANSCRIPT LEVELS (P = 0.006785) AND SIGNIFICANTLY HIGHER JHDM1D (P = 0.0000002) AND HDAC1 (P = 0.010581) TRANSCRIPT LEVELS IN SLE PATIENTS WERE OBSERVED COMPARED WITH HEALTHY CONTROLS. HIGHER JHDM1D MRNA EXPRESSION WAS DETECTED IN ACTIVE SLE PATIENTS WHEN COMPARED WITH INACTIVE PATIENTS (P = 0.005). FURTHERMORE, THE JHDM1D TRANSCRIPT LEVELS WERE POSITIVELY CORRELATED WITH DISEASE ACTIVITY (R(S) = 0.368, P = 0.045), WHILE HDAC2 MRNA EXPRESSION WAS POSITIVELY CORRELATED WITH DISEASE DURATION (R(S) = 0.502, P = 0.0047). CONCLUSION: OUR ANALYSES CONFIRMED THE IMPORTANCE OF EPIGENETIC ALTERATIONS (HISTONE DEMETHYLATION AND ACETYLATION) IN SLE ETIOLOGY. MOREOVER, OUR RESULTS SUGGEST THAT THE PRESENCE OF SOME CLINICAL MANIFESTATIONS, LIKE HEMATOLOGICAL DISEASE AND ANTI-RO ANTIBODY, MIGHT BE ASSOCIATED WITH THE DYSREGULATION OF HISTONE DEMETHYLASE AND DEACETYLASES MRNA EXPRESSION LEVELS. 2015 18 1029 29 CIRCULATING PLASMA MICRORNA IN PATIENTS WITH ACTIVE ACROMEGALY. CONTEXT: EXCESSIVE PRODUCTION OF GROWTH HORMONE CAUSES MARKED MULTIORGAN CHANGES IN PATIENTS WITH ACROMEGALY, WHICH MAY INVOLVE EPIGENETIC MECHANISMS. OBJECTIVE: TO EVALUATE DIFFERENCES IN CIRCULATING MICRORNAS (MIRNAS) ASSOCIATED WITH CHRONIC GROWTH HORMONE OVERPRODUCTION IN ADULTS. DESIGN AND SETTING: A CROSS-SECTIONAL CASE-CONTROL STUDY WAS CONDUCTED AT A TERTIARY MEDICAL CENTER. PARTICIPANTS: WE ENROLLED 12 CONSECUTIVE PATIENTS WITH ACROMEGALY ALONG WITH 12 AGE- AND SEX-MATCHED CONTROLS IN THE DISCOVERY PHASE OF THE STUDY AND THEN EXTENDED THIS COHORT TO 47 PATIENTS WITH ACROMEGALY AND 28 HEALTHY CONTROLS FOR THE VALIDATION STUDY. MAIN OUTCOME MEASURES: PLASMA MIRNAS WERE QUANTIFIED BY NEXT-GENERATION SEQUENCING (NGS) IN THE DISCOVERY PHASE. LEVELS OF SELECTED MIRNAS WERE VALIDATED ON EXTENDED COHORTS USING REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR), COMPARED BETWEEN GROUPS, AND CORRELATED WITH CLINICAL PARAMETERS. RESULTS: BASED ON NGS DATA, WE SELECTED 3 PLASMA MIRNAS DOWNREGULATED IN PATIENTS WITH ACROMEGALY COMPARED TO HEALTHY CONTROLS: MIR-4446-3P -1.317 (P = 0.001), MIR-215-5P -3.040 (P = 0.005), AND MIR-342-5P -1.875 (P = 0.013) WITHOUT MULTIPLICITY CORRECTION FOR ALL 3 MIRNAS. THESE RESULTS WERE CONFIRMED BY RT-QPCR IN THE VALIDATION PHASE FOR 2 MIRNAS OUT OF 3: MIR-4446-3P (P < 0.001, PADJUSTED < 0.001), AREA UNDER THE RECEIVER-OPERATOR CURVE (AUC) 0.862 (95% CI 0.723-0.936; P < 0.001) AND MIR-215-5P (P < 0.001, PADJUSTED < 0.001), AUC 0.829 (95% CI 0.698-0.907; P < 0.001) TO DIFFERENTIATE PATIENTS WITH ACROMEGALY FROM HEALTHY CONTROLS. CONCLUSIONS: IN A 2-PHASE EXPERIMENT USING 2 DIFFERENT TECHNIQUES WE FOUND AND VALIDATED THE DOWNREGULATION OF PLASMA MIR-4446-3P AND MIR-215-5P IN PATIENTS WITH ACROMEGALY COMPARED TO HEALTHY SUBJECTS, WHICH MAKES THEM PROMISING BIOMARKERS FOR FURTHER RESEARCH. 2022 19 1786 31 EFFECT OF ARSENIC EXPOSURE ON NRF2-KEAP1 PATHWAY AND EPIGENETIC MODIFICATION. ARSENIC (AS) IS A KNOWN TOXIC ELEMENT AND CARCINOGEN. TRANSCRIPTION FACTOR NUCLEAR FACTOR-ERYTHROID 2-RELATED FACTOR 2 (NRF2) CONTROLS CELLULAR ADAPTATION TO OXIDANTS AND ELECTROPHILES BY INDUCING ANTIOXIDANT GENES IN RESPONSE TO REDOX STRESS. TO EXPLORE ASSOCIATIONS BETWEEN AS LEVEL AND NRF2-REGULATED CYTOPROTECTIVE GENES EXPRESSION, AN OBSERVATIONAL STUDY WAS CONDUCTED IN A POPULATION OF 61 OCCUPATIONALLY EXPOSED MEN WITH MEDIAN (ME) AGE 50 YEARS (INTERQUARTILE RANGE (IQR) 42-54) AND IN A CONTROL GROUP OF 52 MEN AGED 40 (IQR 31-51.5) WITHOUT OCCUPATIONAL EXPOSURE. NRF2, KEAP1, GSTP1, HMOX1, NQO1, PRDX1, AND TXNRD1 TRANSCRIPT LEVELS WERE DETERMINED BY MEANS OF QUANTITATIVE REAL-TIME PCR ALONG WITH THE GENE EXPRESSION, METHYLATION OF NRF2 AND KEAP1, AS WELL AS GLOBAL DNA METHYLATION WERE ASSESSED. THE MEDIAN URINE AS (TOT.) LEVEL IN THE EXPOSED AND CONTROL GROUP WAS FOUND TO BE 21.8 MUG/G CREAT. (IQR 15.5-39.8 MUG/G CREAT.) AND 3.8 MUG/G CREAT. (IQR 2.5-9.3) (P < 0.001). GLOBAL DNA METHYLATION WAS SIGNIFICANTLY HIGHER IN OCCUPATIONALLY EXPOSED WORKERS THAN IN CONTROLS (ME 14.1 (IQR 9.5-18.1) VS ME 8.5 (IQR 5.9-12.6) P < 0.0001). NRF2 MRNA LEVEL WAS POSITIVELY CORRELATED WITH EXPRESSION OF ALL INVESTIGATED NRF2-TARGET GENES IN BOTH GROUPS (0.37 > R < 0.76, ALL P VALUES < 0.0001). THE MULTIVARIATE LINEAR REGRESSION ADJUSTING FOR GLOBAL METHYLATION SHOWED THAT AS(III) LEVEL WAS SIGNIFICANTLY ASSOCIATED WITH EXPRESSION OF TXNRD1, GSTP1, HMOX1, AND PRDX1. THE RESULTS OF THIS STUDY INDICATE THAT ARSENIC OCCUPATIONAL EXPOSURE IS POSITIVELY ASSOCIATED WITH GLOBAL DNA METHYLATION. THE FINDINGS PROVIDE EVIDENCE FOR RATHER INACTIVATION OF NRF2-KEAP1 PATHWAY IN RESPONSE TO CHRONIC ARSENIC EXPOSURE. 2018 20 6248 24 THE METHYLATION STATUS OF THE DDX43 PROMOTER IN CHINESE PATIENTS WITH CHRONIC MYELOID LEUKEMIA. ABERRANT DNA METHYLATION IS A COMMON EPIGENETIC ALTERATION AND AN IMPORTANT FEATURE IN HUMAN CANCERS. THE DEAD BOX POLYPEPTIDE 43 (DDX43) HAS BEEN FOUND TO BE OVEREXPRESSED IN VARIOUS SOLID TUMORS AND SOME HEMATOLOGIC MALIGNANCIES. IN THE PRESENT STUDY, WE INVESTIGATED THE METHYLATION STATUS OF THE DDX43 PROMOTER IN 87 CHINESE PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) USING REAL-TIME QUANTITATIVE METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION AND EXAMINED THE DDX43 TRANSCRIPT IN 35 PATIENTS USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION. DDX43 PROMOTER HYPOMETHYLATION WAS OBSERVED IN 22 (25.3%) CML PATIENTS. NO SIGNIFICANT CORRELATION WAS FOUND BETWEEN THE HYPOMETHYLATION OF THE DDX43 PROMOTER WITH THE AGE, SEX, WHITE BLOOD CELL COUNTS, HEMOGLOBIN CONCENTRATION, PLATELET COUNTS, AND CHROMOSOMAL ABNORMALITIES OF CML PATIENTS (P>0.05). THE FREQUENCY OF DDX43 HYPOMETHYLATION IN PATIENTS IN THE CHRONIC PHASE, IN THE ACCELERATED PHASE, AND IN BLAST CRISIS WAS 23.4% (15/64), 25.0% (2/8), AND 33.3% (5/15), RESPECTIVELY (P>0.05). THERE WAS A SIGNIFICANT CORRELATION BETWEEN DDX43 HYPOMETHYLATION AND DDX43 TRANSCRIPT (R=0.469, P=0.004). OUR DATA SUGGEST THAT HYPOMETHYLATION OF THE DDX43 PROMOTER MAY BE AN EARLY AND FREQUENT MOLECULAR EVENT IN THE DEVELOPMENT OF CML IN CHINESE PATIENTS. 2013